Cargando…

Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients

BACKGROUND: No study has compared the long-term prognoses of hepatitis C patients with hepatitis C virus (HCV) antibody-negative individuals and investigated the effects of interferon (IFN) treatment. To clarify the long-term prognosis of HCV-positive residents of an isolated Japanese island and pro...

Descripción completa

Detalles Bibliográficos
Autores principales: Yamasaki, Kazumi, Tomohiro, Mayumi, Nagao, Yumiko, Sata, Michio, Shimoda, Toshiaki, Hirase, Kazuhiro, Shirahama, Satoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2012
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502559/
https://www.ncbi.nlm.nih.gov/pubmed/23057417
http://dx.doi.org/10.1186/1471-230X-12-139
_version_ 1782250367181914112
author Yamasaki, Kazumi
Tomohiro, Mayumi
Nagao, Yumiko
Sata, Michio
Shimoda, Toshiaki
Hirase, Kazuhiro
Shirahama, Satoshi
author_facet Yamasaki, Kazumi
Tomohiro, Mayumi
Nagao, Yumiko
Sata, Michio
Shimoda, Toshiaki
Hirase, Kazuhiro
Shirahama, Satoshi
author_sort Yamasaki, Kazumi
collection PubMed
description BACKGROUND: No study has compared the long-term prognoses of hepatitis C patients with hepatitis C virus (HCV) antibody-negative individuals and investigated the effects of interferon (IFN) treatment. To clarify the long-term prognosis of HCV-positive residents of an isolated Japanese island and prospectively investigate the effects of IFN treatment in comparison with the HCV-negative general population. METHODS: HCV antibody was positive in 1,343 (7.6%) of the 17,712 individuals screened. 792 HCV RNA-positive, HBsAg-negative subjects were enrolled. 1,584 HCV antibody-negative, HBsAg-negative general residents were sex- and age-matched to the 792 subjects. A total of 154 <70-year-old patients without liver cirrhosis (LC) or hepatocellular carcinoma (HCC) underwent IFN treatment. The survival rate with all-cause death as the endpoint was determined and causes of death were compared. RESULTS: The 10- and 20-year survival rates of the hepatitis C and general resident groups were 65.4% and 87.8%, and 40.8% and 62.5%, respectively (p < 0.001; hazard risk ratio, 0.444; 95% confidence interval (CI): 0.389–0.507). There were 167 liver disease-related deaths and 223 deaths from other causes in the hepatitis C group, and 7 and 451, respectively, in the general resident group. Liver disease-related death accounted for 43.8% and 1.5% of deaths in the hepatitis C and general resident groups (p < 0.0001). The cumulative survival rate of the hepatitis C patients without IFN (n = 328) was significantly lower than the gender- and age-matched general resident group (n = 656) (p < 0.0001) but there was no significant difference between the IFN-treated (n = 154) and general resident groups (n = 308). CONCLUSIONS: In the hepatitis C group, the proportion of liver disease-related death was markedly higher, and the survival rate lower, than the general resident group. Introduction of IFN treatment in <70-year-old patients with hepatitis C without LC or HCC improved the survival rate to a level comparable to that of the general residents.
format Online
Article
Text
id pubmed-3502559
institution National Center for Biotechnology Information
language English
publishDate 2012
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-35025592012-11-22 Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients Yamasaki, Kazumi Tomohiro, Mayumi Nagao, Yumiko Sata, Michio Shimoda, Toshiaki Hirase, Kazuhiro Shirahama, Satoshi BMC Gastroenterol Research Article BACKGROUND: No study has compared the long-term prognoses of hepatitis C patients with hepatitis C virus (HCV) antibody-negative individuals and investigated the effects of interferon (IFN) treatment. To clarify the long-term prognosis of HCV-positive residents of an isolated Japanese island and prospectively investigate the effects of IFN treatment in comparison with the HCV-negative general population. METHODS: HCV antibody was positive in 1,343 (7.6%) of the 17,712 individuals screened. 792 HCV RNA-positive, HBsAg-negative subjects were enrolled. 1,584 HCV antibody-negative, HBsAg-negative general residents were sex- and age-matched to the 792 subjects. A total of 154 <70-year-old patients without liver cirrhosis (LC) or hepatocellular carcinoma (HCC) underwent IFN treatment. The survival rate with all-cause death as the endpoint was determined and causes of death were compared. RESULTS: The 10- and 20-year survival rates of the hepatitis C and general resident groups were 65.4% and 87.8%, and 40.8% and 62.5%, respectively (p < 0.001; hazard risk ratio, 0.444; 95% confidence interval (CI): 0.389–0.507). There were 167 liver disease-related deaths and 223 deaths from other causes in the hepatitis C group, and 7 and 451, respectively, in the general resident group. Liver disease-related death accounted for 43.8% and 1.5% of deaths in the hepatitis C and general resident groups (p < 0.0001). The cumulative survival rate of the hepatitis C patients without IFN (n = 328) was significantly lower than the gender- and age-matched general resident group (n = 656) (p < 0.0001) but there was no significant difference between the IFN-treated (n = 154) and general resident groups (n = 308). CONCLUSIONS: In the hepatitis C group, the proportion of liver disease-related death was markedly higher, and the survival rate lower, than the general resident group. Introduction of IFN treatment in <70-year-old patients with hepatitis C without LC or HCC improved the survival rate to a level comparable to that of the general residents. BioMed Central 2012-10-12 /pmc/articles/PMC3502559/ /pubmed/23057417 http://dx.doi.org/10.1186/1471-230X-12-139 Text en Copyright ©2012 Yamasaki et al.; licensee BioMed Central Ltd. http://creativecommons.org/licenses/by/2.0 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Yamasaki, Kazumi
Tomohiro, Mayumi
Nagao, Yumiko
Sata, Michio
Shimoda, Toshiaki
Hirase, Kazuhiro
Shirahama, Satoshi
Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
title Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
title_full Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
title_fullStr Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
title_full_unstemmed Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
title_short Effects and Outcomes of Interferon Treatment in Japanese Hepatitis C Patients
title_sort effects and outcomes of interferon treatment in japanese hepatitis c patients
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3502559/
https://www.ncbi.nlm.nih.gov/pubmed/23057417
http://dx.doi.org/10.1186/1471-230X-12-139
work_keys_str_mv AT yamasakikazumi effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients
AT tomohiromayumi effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients
AT nagaoyumiko effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients
AT satamichio effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients
AT shimodatoshiaki effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients
AT hirasekazuhiro effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients
AT shirahamasatoshi effectsandoutcomesofinterferontreatmentinjapanesehepatitiscpatients